NASDAQ
191.31USD
+1.04 (+0.55%)
We have scored 44 news catalysts on Revolution Medicines, Inc. (RVMD) over the past 12 months. The biggest single-day move next to one of them came Jun 29, 2026, when RVMD closed +5.8%: “Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS”. Coverage across the window leans positive (average ticker sentiment +0.44). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
41B
P/E
—
EPS
—
Beta
1.40
52W range
56.66-224.31
Day range
187.28–192.72
Open
188.44
Prev close
190.27
Volume
1.1M
Avg volume
2.1M
Dividend
0.00
IPO
2020-02-13
Analysts publish price targets on RVMD, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
28 analyst price targets from $175 to $320
as of 2026-09-23
The market is 17% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Revolution Medicines, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Revolution Medicines, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for RVMD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
The reconstruction
At $191, the stock sits at the 14th percentile of published models, leaning bearish against the analyst consensus and refusing to pay for 17 bull cases that project targets 15% to 68% higher.
What the disagreement turns on
The central question is whether daraxonrasib's early 42% objective response rate in NSCLC translates into a successful Phase 3 outcome and major new revenue, but the available data tools cannot measure drug prescription volumes or clinical trial results, making this untestable with wired data.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
